Small capital stocks in the Biotechnology & Drugs industry can be as risky as they are attractive. This is because new active substances may not cross all regulatory hurdles. This stock is an exception. Its technology is exclusive and relevant. Yet, the chances of its existing US Food and Drug Administration (FDA) clearances being extended to other countries and therapeutic areas are extremely good. The company offers a new delivery system rather than new molecules. The technology is versatile and can be applied to any pharmaceutical substance.

Who has never forgotten to take a pill on time? Nearly universal fears about injections make it tremendously attractive to be able to take shots less often. Infections, psychiatric disorders, chronic pain, incurable diseases, and disturbed sleep are the areas which this company’s platform technology addresses

Both health care givers and patients can realize appreciable benefits from the company’s know-how. The management team has done well to focus on antibiotics, neurology, psychiatry, pain management, menopause, gastric reflux, and diabetes. Reduced dosing frequency is advantageous in each of these areas.

The Trailing Twelve Months Net Profit Margin is over 75%, business performance has improved sharply at the end of the Most Recent Quarter, ongoing clinical trial results look promising, and new regulatory clearances from Europe are likely. The stock seems precisely the kind of opportunity that investors would like from the Healthcare Sector.

Let us hear your thoughts below: